CRISPR Therapeutics AG (CRSP) Total Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Total Liabilities across 12 years of filings, most recently posting $911.3 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $911.3 million, up 170.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $911.3 million (up 170.45% YoY), and the FY2025 annual result was $343.4 million, up 10.8% from the prior year.
• Total Liabilities came in at $911.3 million for Q1 2026 at CRISPR Therapeutics AG, up from $343.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $911.3 million in Q1 2026 to a low of $310.0 million in Q4 2024.
• The 5-year median for Total Liabilities is $358.9 million (2024), against an average of $385.7 million.
• Across the five-year window, Total Liabilities fell 11.86% in 2024 and surged 170.45% in 2026, its largest moves.
• CRISPR Therapeutics AG's Total Liabilities stood at $367.6 million in 2022, then declined by 5.66% to $346.8 million in 2023, then fell by 10.62% to $310.0 million in 2024, then climbed by 10.8% to $343.4 million in 2025, then soared by 165.34% to $911.3 million in 2026.
• The last three Total Liabilities figures came in at $911.3 million (Q1 2026), $343.4 million (Q4 2025), and $329.3 million (Q3 2025), per Business Quant data.